Zobrazeno 1 - 10 of 33 pro vyhledávání: '"Bakardjiev AI"'
1
In Vivo Virulence Characterization of Pregnancy-Associated Listeria monocytogenes Infections
Autor: Robbins, Bakardjiev Ai, Lowe D, Morrison Ha
Publikováno v: Infection and Immunity
Listeria monocytogenes is a foodborne pathogen that infects the placenta and can cause pregnancy complications. Listeriosis usually occurs as a sporadic infection, but large outbreaks are also reported.
Listeria monocytogenes is a foodborne path
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0b012559c3663126074440da02749d5
https://doi.org/10.1128/iai.00397-18
Zobrazit plný text záznamu
2
First trimester typhoid Fever with vertical transmission of salmonella typhi, an intracellular organism
Autor: Bakardjiev, Anna, Vigliani, MB, Bakardjiev, AI
Publikováno v: Bakardjiev, Anna; Vigliani, MB; & Bakardjiev, AI. (2013). First trimester typhoid Fever with vertical transmission of salmonella typhi, an intracellular organism.. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/52z5v2s6
We report a case in which placental abruption occurred at 16 weeks following first trimester diagnosis and treatment for typhoid fever. Unexpectedly Salmonella enterica serovar Typhi (S. Typhi) was found in fetal tissues at autopsy. Using information
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::3d1d32128d781ddaf7490f4555c2169c
http://www.escholarship.org/uc/item/52z5v2s6
Zobrazit plný text záznamu
3
Placental Syncytium Forms a Biophysical Barrier against Pathogen Invasion
Autor: Maltepe, Emin, Bakardjiev, Anna, Zeldovich, VB, Clausen, CH, Bradford, E, Fletcher, DA, Robbins, JR, Bakardjiev, AI
Publikováno v: Maltepe, Emin; Bakardjiev, Anna; Zeldovich, VB; Clausen, CH; Bradford, E; Fletcher, DA; et al.(2013). Placental Syncytium Forms a Biophysical Barrier against Pathogen Invasion. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/53x7n02r
Fetal syncytiotrophoblasts form a unique fused multinuclear surface that is bathed in maternal blood, and constitutes the main interface between fetus and mother. Syncytiotrophoblasts are exposed to pathogens circulating in maternal blood, and appear
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::e47fb2d755ec889a1bad28d5167d3497
http://www.escholarship.org/uc/item/53x7n02r
Zobrazit plný text záznamu
4
Host Defense and Tolerance: Unique Challenges in the Placenta
Autor: Bakardjiev, Anna, Zeldovich, VB, Bakardjiev, AI
Publikováno v: Bakardjiev, Anna; Zeldovich, VB; & Bakardjiev, AI. (2012). Host Defense and Tolerance: Unique Challenges in the Placenta. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/9rz9v7wx
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::4a8d0028a45a2eb20e295cbd689ebdca
http://www.escholarship.org/uc/item/9rz9v7wx
Zobrazit plný text záznamu
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
9
Akademický článek
DNL343 is an investigational CNS penetrant eukaryotic initiation factor 2B activator that prevents and reverses the effects of neurodegeneration caused by the integrated stress response.
Autor: Yulyaningsih E; Denali Therapeutics, South San Francisco, United States., Suh JH; Denali Therapeutics, South San Francisco, United States., Fanok M; Denali Therapeutics, South San Francisco, United States., Chau R; Denali Therapeutics, South San Francisco, United States., Solanoy H; Denali Therapeutics, South San Francisco, United States., Takahashi R; Denali Therapeutics, South San Francisco, United States., Bakardjiev AI; Denali Therapeutics, South San Francisco, United States., Becerra I; Denali Therapeutics, South San Francisco, United States., Benitez NB; Denali Therapeutics, South San Francisco, United States., Chiu CL; Denali Therapeutics, South San Francisco, United States., Davis SS; Denali Therapeutics, South San Francisco, United States., Dowdle WE; Denali Therapeutics, South San Francisco, United States., Earr T; Denali Therapeutics, South San Francisco, United States., Estrada AA; Denali Therapeutics, South San Francisco, United States., Gill A; Denali Therapeutics, South San Francisco, United States., Ha C; Denali Therapeutics, South San Francisco, United States., Haddick PCG; Denali Therapeutics, South San Francisco, United States., Henne KR; Denali Therapeutics, South San Francisco, United States., Larhammar M; Denali Therapeutics, South San Francisco, United States., Leung AW; Denali Therapeutics, South San Francisco, United States., Maciuca R; Denali Therapeutics, South San Francisco, United States., Memarzadeh B; Denali Therapeutics, South San Francisco, United States., Nguyen HN; Denali Therapeutics, South San Francisco, United States., Nugent AA; Denali Therapeutics, South San Francisco, United States., Osipov M; Denali Therapeutics, South San Francisco, United States., Ran Y; Denali Therapeutics, South San Francisco, United States., Rebadulla K; Denali Therapeutics, South San Francisco, United States., Roche E; Denali Therapeutics, South San Francisco, United States., Sandmann T; Denali Therapeutics, South San Francisco, United States., Wang J; Denali Therapeutics, South San Francisco, United States., Lewcock JW; Denali Therapeutics, South San Francisco, United States., Scearce-Levie K; Denali Therapeutics, South San Francisco, United States., Kane LA; Denali Therapeutics, South San Francisco, United States., Sanchez PE; Denali Therapeutics, South San Francisco, United States.
Publikováno v: ELife [Elife] 2024 Sep 17; Vol. 12. Date of Electronic Publication: 2024 Sep 17.
Zobrazit plný text záznamu
10
Akademický článek
Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials.
Autor: Gane E; University of Auckland and New Zealand Clinical Research, Auckland, New Zealand. Electronic address: EdGane@adhb.govt.nz., Lim YS; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Kim JB; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Jadhav V; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Shen L; Vir Biotechnology, Inc., San Francisco, California, USA., Bakardjiev AI; Vir Biotechnology, Inc., San Francisco, California, USA., Huang SA; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Cathcart AL; Vir Biotechnology, Inc., San Francisco, California, USA., Lempp FA; Vir Biotechnology, Inc., San Francisco, California, USA., Janas MM; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Cloutier DJ; Vir Biotechnology, Inc., San Francisco, California, USA., Kaittanis C; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Sepp-Lorenzino L; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Hinkle G; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Taubel J; Richmond Pharmacology Ltd., St George's University of London, London, UK., Haslett P; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Milstein S; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Anglero-Rodriguez YI; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Hebner CM; Vir Biotechnology, Inc., San Francisco, California, USA., Pang PS; Vir Biotechnology, Inc., San Francisco, California, USA., Yuen MF; Department of Medicine and State Key Laboratory of Liver Research, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
Publikováno v: Journal of hepatology [J Hepatol] 2023 Oct; Vol. 79 (4), pp. 924-932. Date of Electronic Publication: 2023 Jun 07.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje